Estimation of Functional Liver Reserve Using Cholinesterases
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00883454 |
Recruitment Status
:
Completed
First Posted
: April 17, 2009
Last Update Posted
: April 17, 2009
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease |
---|
Hepatocellular Carcinoma Cirrhosis Liver Neoplasm Liver Disease |
Study Type : | Observational |
Actual Enrollment : | 181 participants |
Observational Model: | Cohort |
Time Perspective: | Retrospective |
Official Title: | Estimation of Functional Liver Reserve in Patients With Hepatocellular Carcinoma in Cirrhosis: the Value of Preoperative Cholinesterases |

- The primary outcome was to investigate the value of preoperative cholinesterases in predict postoperative adverse outcome after hepatic resection for hepatocellular carcinoma in cirrhosis.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 90 Years (Adult, Senior) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- Total bilirubin < 2 mg/dl
- No ascites
- No esophageal varices, or esophageal varices eradicated by endoscopy
-
Liver volume:
- residual liver volume > or = 40% if total bilirubin < 1 mg/dl
- residual liver volume > or = 50% if total bilirubin between 1 and 1.5 mg/dl
- only limited resection if total bilirubin > 1.5 mg/dl
- Portal vein embolization was selected in any case in whom RLV did not fit the previous requirements.
Exclusion Criteria:
- Total bilirubin > 2 mg/dl
- Refractory ascites
- Esophageal varices

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00883454
Italy | |
Liver Surgery Unit, Third Department of Surgery, University of MIlan, IRCCS Istituto Clinico Humanitas | |
Rozzano, Milan, Milan, Italy, 20089 |
ClinicalTrials.gov Identifier: | NCT00883454 History of Changes |
Other Study ID Numbers: |
CHE-HCC |
First Posted: | April 17, 2009 Key Record Dates |
Last Update Posted: | April 17, 2009 |
Last Verified: | April 2009 |
Keywords provided by University of Milan:
hepatocellular carcinoma liver tumor cirrhosis |
liver resection tumor staging liver disease staging |
Additional relevant MeSH terms:
Carcinoma Carcinoma, Hepatocellular Fibrosis Liver Cirrhosis Liver Diseases Liver Neoplasms Neoplasms, Glandular and Epithelial |
Neoplasms by Histologic Type Neoplasms Adenocarcinoma Digestive System Neoplasms Neoplasms by Site Digestive System Diseases Pathologic Processes |